{
    "symbol": "SMTI",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-17 10:33:01",
    "content": " Breaking down first quarter SG&A further, total costs related to commissions and selling fees were $3.2 million. Total Sanara costs related to compensation and benefits were $2.9 million, excluding compensation and benefits for Rochal and WounDerm, which were $300,000 and $200,000, respectively. Total costs related to Rochal Technologies were $600,000; total costs related to WounDerm were $800,000, including $450,000 in transaction costs associated with our Precision Healing merger. The higher SG&A expenses in 2022 were primarily due to increased selling costs resulting from our sales force expansion and operational support, higher sales commission expense as a result of higher product sales, higher non-cash equity compensation costs and higher payroll costs related to the addition of the Rochal workforce in July 2021. Breaking down first quarter SG&A further, total costs related to commissions and selling fees were $3.2 million. Total costs related to compensation and benefits were $2.9 million, excluding Rochal and WounDerm, which accounted for $300,000 and $200,000, respectively. Total costs related to WounDerm were $800,000, including $450,000 in transaction costs associated with the Precision Healing merger. Higher R&D costs increased by $100,000 and higher non-cash losses related to our equity method Investment in Precision Healing increased by approximately $300,000 year-over-year."
}